In our sample, 2 of 6 patients with a KRAS mutation (33%) had some degree of heterogeneity found in the sample; therefore, a recommendation can be made that that at least two biopsies from different parts of the tumour be taken to take the heterogeneity into consideration. Here, KRAS is linked to neoplasm.